Onishi A, Tanaka M, Fujii T, Murata K, et al. Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther 2025;27:52.
PMID: 40055759